Dr. Asha L. Bailey, DO
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 497
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Philadelphia College of Osteopathic Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
SC license 1541 · MS license 34462 · TN license 6022
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Prisma Health Richland Hospital Columbia, SC
- Lexington Medical Center West Columbia, SC
- Prisma Health Baptist Columbia, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Prisma Health Baptist PArkridge Columbia, SC
Medical groups
- Columbia Nephrology Associates PA (33 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 497
- Services billed
- 3,443
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Total protein level, urine | 290 | 177 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 289 | 139 |
| Creatinine level to test for kidney function or muscle injury | 289 | 176 |
| Kidney function blood test panel | 278 | 167 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 276 | 166 |
| Manual urinalysis test with examination using microscope, automated | 260 | 159 |
| Insertion of needle into vein for collection of blood sample | 251 | 144 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 250 | 53 |
| Parathormone (parathyroid hormone) level | 238 | 152 |
| Established patient office or other outpatient visit, 30-39 minutes | 214 | 151 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Columbia, SC | 165 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Columbia, SC | 124 |
| Amlodipine Besylate Other prescribers in Columbia, SC | 89 |
| Velphoro (sucroferric oxyhydroxide) | 70 |
| Losartan Potassium Other prescribers in Columbia, SC | 62 |
| Calcitriol Other prescribers in Columbia, SC | 62 |
| Metolazone Other prescribers in Columbia, SC | 35 |
| Metoprolol Succinate Other prescribers in Columbia, SC | 33 |
| Jardiance (empagliflozin) Other prescribers in Columbia, SC | 33 |
| Spironolactone Other prescribers in Columbia, SC | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 44 payments worth $902 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $346 |
|---|---|
| Calliditas Therapeutics US Inc. | $142 |
| AstraZeneca Pharmaceuticals LP | $93.36 |
| Amgen Inc. | $88.58 |
| Novo Nordisk Inc | $46.56 |
| Fresenius USA Marketing, Inc. | $38.45 |
| Scpharmaceuticals Inc. | $37.15 |
| Ardelyx, Inc. | $26.97 |
| Food and Beverage | $902 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $254,998 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
Novartis Pharmaceuticals Corporation - Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.